For a glucose-lowering drug to be included as a comparator, it was required to have been evaluated in at least one trial comparison against tirzepatide and one trial comparison against semaglutide
van der Vos KE, Eliasson P, Proikas-Cezanne T, Vervoort SJ, van Boxtel R, Putker M, van Zutphen IJ, Mauthe M, Zellmer S, Pals C, Verhagen LP, Groot Koerkamp MJ, Braat AK, Dansen TB, Holstege FC, Gebhardt R, Burgering BM, Coffer PJ
10.1016/j.ica.2008.11.003
Understanding that Rybelsus acts through appetite regulation, satiety, and gastric emptying, rather than through any single dramatic effect, sets realistic expectations
Some even saw extra progress during a gradual taper
Managing Side Effects of GLP-1 Receptor Agonists. Clinical Diabetes , 2019